Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACE-031 (ActRIIB-IgG1) in Subjects With Duchenne Muscular Dystrophy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Ramatercept (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Acceleron Pharma
- 15 May 2014 New trial record